Form 4: CytoMed Therapeutics Director Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Chee Kong Choo, a Director and 10% owner of CytoMed Therapeutics Ltd, reported multiple transactions in common stock on July 14, 2026.

Summary

  • Open-market purchase: disposed of 100,000 ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED at $1.50 ($150,000) on July 14, 2026; holds 530,324 after (Direct).
  • Open-market purchase: disposed of 100,000 ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED at $1.50 ($150,000) on July 20, 2026; holds 630,324 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Chee Kong Choo — Director, 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2026-07-14Open-market purchaseORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED100,000$2$150.0K530,324
2026-07-20Open-market purchaseORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED100,000$2$150.0K630,324

Key Dates

DateDescription
2026-07-14Open-market purchase (100,000 shares)
2026-07-20Open-market purchase (100,000 shares)

Keywords

insider transaction, Form 4, GDTC, CytoMed Therapeutics Ltd, neutral, Chee Kong Choo

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.